vs
Side-by-side financial comparison of A2Z CUST2MATE SOLUTIONS CORP. (AZ) and Context Therapeutics Inc. (CNTX). Click either name above to swap in a different company.
A2Z CUST2MATE SOLUTIONS CORP. is the larger business by last-quarter revenue ($1.5M vs $1.2M, roughly 1.2× Context Therapeutics Inc.). A2Z CUST2MATE SOLUTIONS CORP. runs the higher net margin — -90.4% vs -1403.9%, a 1313.4% gap on every dollar of revenue. On growth, Context Therapeutics Inc. posted the faster year-over-year revenue change (328.2% vs -1.6%).
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative targeted therapies for hormone-driven cancers. Its core pipeline includes candidates for breast, ovarian and other gynecologic malignancies, primarily serving oncology patient populations across North America and Europe.
AZ vs CNTX — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2024
| Metric | | |
|---|---|---|
| Revenue | $1.5M | $1.2M |
| Net Profit | $-1.4M | $-17.5M |
| Gross Margin | 34.0% | — |
| Operating Margin | -265.9% | -1503.7% |
| Net Margin | -90.4% | -1403.9% |
| Revenue YoY | -1.6% | 328.2% |
| Net Profit YoY | 60.4% | -197.2% |
| EPS (diluted) | — | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $1.5M | — | ||
| Q2 25 | $1.2M | — | ||
| Q1 25 | $2.0M | — | ||
| Q3 24 | $1.6M | $1.2M | ||
| Q2 24 | $1.1M | $840.1K | ||
| Q4 23 | — | $224.7K | ||
| Q3 23 | — | $290.4K | ||
| Q2 23 | — | $293.3K |
| Q3 25 | $-1.4M | — | ||
| Q2 25 | $-12.6M | — | ||
| Q1 25 | $-6.8M | — | ||
| Q3 24 | $-3.5M | $-17.5M | ||
| Q2 24 | $-3.2M | $-2.3M | ||
| Q4 23 | — | $-6.8M | ||
| Q3 23 | — | $-5.9M | ||
| Q2 23 | — | $-5.0M |
| Q3 25 | 34.0% | — | ||
| Q2 25 | 23.3% | — | ||
| Q1 25 | 31.7% | — | ||
| Q3 24 | 43.9% | — | ||
| Q2 24 | 7.4% | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q3 25 | -265.9% | — | ||
| Q2 25 | -585.9% | — | ||
| Q1 25 | -381.4% | — | ||
| Q3 24 | -167.0% | -1503.7% | ||
| Q2 24 | -272.1% | -367.6% | ||
| Q4 23 | — | -3085.3% | ||
| Q3 23 | — | -2128.0% | ||
| Q2 23 | — | -1804.6% |
| Q3 25 | -90.4% | — | ||
| Q2 25 | -1085.4% | — | ||
| Q1 25 | -342.1% | — | ||
| Q3 24 | -224.7% | -1403.9% | ||
| Q2 24 | -277.4% | -268.3% | ||
| Q4 23 | — | -3012.6% | ||
| Q3 23 | — | -2022.7% | ||
| Q2 23 | — | -1708.8% |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $-0.19 | — | ||
| Q3 24 | $-0.15 | $-0.22 | ||
| Q2 24 | $-0.05 | $-0.04 | ||
| Q4 23 | — | $-0.42 | ||
| Q3 23 | — | $-0.37 | ||
| Q2 23 | — | $-0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $43.2M | $84.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $71.3M | $83.9M |
| Total Assets | $81.9M | $86.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $43.2M | — | ||
| Q2 25 | $28.5M | — | ||
| Q1 25 | $24.2M | — | ||
| Q3 24 | $3.4M | $84.8M | ||
| Q2 24 | $653.0K | $101.5M | ||
| Q4 23 | — | $14.4M | ||
| Q3 23 | — | $21.7M | ||
| Q2 23 | — | $25.1M |
| Q3 25 | $71.3M | — | ||
| Q2 25 | $31.5M | — | ||
| Q1 25 | $31.3M | — | ||
| Q3 24 | $-504.0K | $83.9M | ||
| Q2 24 | $-340.0K | $101.1M | ||
| Q4 23 | — | $11.9M | ||
| Q3 23 | — | $18.4M | ||
| Q2 23 | — | $24.0M |
| Q3 25 | $81.9M | — | ||
| Q2 25 | $46.1M | — | ||
| Q1 25 | $42.2M | — | ||
| Q3 24 | $10.2M | $86.3M | ||
| Q2 24 | $7.2M | $102.7M | ||
| Q4 23 | — | $16.1M | ||
| Q3 23 | — | $23.0M | ||
| Q2 23 | — | $27.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.0M | $-1.9M |
| Free Cash FlowOCF − Capex | — | $-1.9M |
| FCF MarginFCF / Revenue | — | -156.0% |
| Capex IntensityCapex / Revenue | — | 0.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-4.0M | — | ||
| Q2 25 | $-5.9M | — | ||
| Q1 25 | $-3.8M | — | ||
| Q3 24 | $-658.0K | $-1.9M | ||
| Q2 24 | $-3.7M | $-3.4M | ||
| Q4 23 | — | $-7.2M | ||
| Q3 23 | — | $-3.5M | ||
| Q2 23 | — | $-4.6M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | $-1.9M | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | -156.0% | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | — | 0.0% | ||
| Q4 23 | — | 0.0% | ||
| Q3 23 | — | 0.0% | ||
| Q2 23 | — | 0.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
